Sandbox Reserved 1066: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 49: | Line 49: | ||
''Mycobacterium tuberculosis'' ''(M.tb)'' is the causative agent involved in the disease '''tuberculosis'''. Tuberculosis is a growing global health concern that has been intensified due to the increase in HIV infections along with the increase in multi-drug resistance strains of ''(M. tb)'' <ref name="molecular studies">PMID: 20454815</ref>. Most of the drug resistance has evolved due to the intensive nature of the treatment for tuberculosis, which often goes incomplete thus resulting in drug resistant strains; therefore, the importance in identifying characteristics and residues to be exploited for new drug targets is pivotal <ref name="molecular studies"/>. | ''Mycobacterium tuberculosis'' ''(M.tb)'' is the causative agent involved in the disease '''tuberculosis'''. Tuberculosis is a growing global health concern that has been intensified due to the increase in HIV infections along with the increase in multi-drug resistance strains of ''(M. tb)'' <ref name="molecular studies">PMID: 20454815</ref>. Most of the drug resistance has evolved due to the intensive nature of the treatment for tuberculosis, which often goes incomplete thus resulting in drug resistant strains; therefore, the importance in identifying characteristics and residues to be exploited for new drug targets is pivotal <ref name="molecular studies"/>. | ||
The cell wall of ''(M. tb)'' is known to be composed and synthesized from a distinct variety of lipids, most notably mycolic acids, which are known to play a crucial role in the pathogenesis of ''(M. tb)'' <ref name="molecular studies"/>. | The cell wall of ''(M. tb)'' is known to be composed and synthesized from a distinct variety of lipids, most notably mycolic acids, which are known to play a crucial role in the pathogenesis of ''(M. tb)'' <ref name="molecular studies"/> | ||
== Current Treatment == | |||
Currently the treatment for active cases of tuberculosis include the simultaneous therapeutic use of two or more frontline drugs: isoniazid, ethambutol, rifampicin and pyrazinamide. <ref name="molecular studies"/> | |||
<ref name="Drug Inhibitors">PMID: 12164478</ref> | |||
== Relevance of key mutational studies to the understanding and development of new inhibitors for FadD13 == | == Relevance of key mutational studies to the understanding and development of new inhibitors for FadD13 == | ||
| Line 55: | Line 60: | ||
<ref name="residue paper"/> | <ref name="residue paper"/> | ||
== Future Research == | |||
While currently there are no specific drug targets for FadD13, a better understanding of key residues involved in the activation of very-long-chain fatty acids is a promising start to developing new drug targets for ''(M. tb)''. | While currently there are no specific drug targets for FadD13, a better understanding of key residues involved in the activation of very-long-chain fatty acids is a promising start to developing new drug targets for ''(M. tb)''. | ||
</StructureSection> | </StructureSection> | ||
